8-methyl-5-(4-nitrophenyl)-8,9-dihydro-7H-(1,3)-dioxolo-[4,5-h][2,3]benzodiazepine | 161832-63-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 8-methyl-5-(4-nitrophenyl)-8,9-dihydro-7H-(1,3)-dioxolo-[4,5-h][2,3]benzodiazepine
• 英文别名: 1-(4-Nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine；5-(4-nitrophenyl)-8-methyl-9H-7H-1,3-dioxolo[4,5-h][2,3]-benzodiazepine；(+/-)-7,8-dihydro-8-methyl-5-(4-nitrophenyl)-9H-1,3-dioxolo/4,5-h//2,3/benzodiazepine；8-methyl-5-(4-nitrophenyl)-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepine
• CAS: 161832-63-9
• 化学式: C₁₇H₁₅N₃O₄
• 分子量: 325.324
• InChiKey: DJXIVFHYOLZSBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  88.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  8-methyl-5-(4-nitrophenyl)-8,9-dihydro-7H-(1,3)-dioxolo-[4,5-h][2,3]benzodiazepine 在 三甲基氯硅烷 、 三乙胺 、 肼 作用下， 以 四氢呋喃 、 氯仿 、 甲苯 为溶剂， 反应 25.5h， 生成 (+/-)-1-{8-methyl-5-(4-nitrophenyl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carbothioyl}-4-methyl-semicarbazide
  参考文献：
  名称：

  Novel substituted 2,3-benzodiazepine derivatives

  摘要：

  这项发明涉及新的2,3-苯二氮杂环衍生物的公式(I)，其异构体和酸盐，以及含有它们的药物组合物，以及适用于治疗与肌肉痉挛、癫痫、急性和慢性神经退行性疾病相关症状的药物组合物和使用方法，以及预防、治疗或缓解急性和慢性炎症性疾病症状的方法。

  公开号：

  US20040152693A1
• 作为产物：
  描述：

  (S)-(-)-2-氨基-3-甲基-1,1-二苯基-1-丁醇 、 5-(4-nitrophenyl)-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine 在 硼烷 、 sodium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 8-methyl-5-(4-nitrophenyl)-8,9-dihydro-7H-(1,3)-dioxolo-[4,5-h][2,3]benzodiazepine
  参考文献：
  名称：

  N-acyl-2,3-benzodiazepine derivatives, pharmaceutical compositions

  摘要：

  这项发明涉及一种新颖的N-酰基-2,3-苯并二氮杂平衍生物，其一般式为（I），它们的立体异构体和酸盐，含有它们的药物组合物以及它们的制备方法。在一般式（I）中，根据规范定义，可以找到化合物的更完整描述。一般式（I）的化合物具有有价值的中枢神经系统效应，特别是肌肉松弛、抗惊厥和神经保护作用。因此，它们可能对治疗各种中枢神经系统起源的疾病有用。

  公开号：

  US05459137A1

文献信息

• N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of
  申请人：Gyogyszerkutato Intezet Kv.

  公开号：US05521174A1

  公开（公告）日：1996-05-28

  The invention relates to novel N-acyl-2,3-benzodiezapine derivatives and a method of treating spasms of the skeletal musculature therewith.

  这项发明涉及新颖的N-酰基-2,3-苯并二氮杂平衍生物及其治疗骨骼肌肉痉挛的方法。
• N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions
  申请人：Gyogyszerkutato Intezet

  公开号：US05519019A1

  公开（公告）日：1996-05-21

  The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) R stands for a C.sub.1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C.sub.1-4 alkylamino, di(C.sub.1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C.sub.1-5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R.sup.1 means hydrogen; or R.sup.1 is absent when a double bond exists between the N(3) and C(4) atoms; R.sup.2 means a C.sub.1-3 alkyl group; or R.sup.1 and R.sup.2 together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R.sup.3 means hydrogen or a C.sub.1-4 alkanoyl group; R.sup.4 represents hydrogen; a C.sub.1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C.sub.1-4 alkylamino, di(C.sub.1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropane-carbonyl, C.sub.1-5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R.sup.3 and R.sup.4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

  该发明涉及一种新颖的N-酰基-2,3-苯并二氮杂平衍生物，其一般式为(I)，它们的立体异构体和酸盐，含有它们的药物组合物以及它们的制备方法。在一般式(I)中，R代表一个C.sub.1-6烷酰基，可选地被一个甲氧基，氰基，羧基，氨基，C.sub.1-4烷基氨基，二(C.sub.1-4烷基)氨基，吡咯烷基，邻苯二甲酰亚胺基或苯基取代，或者一个或多个卤素; 或者R是苯甲酰基，环丙烷羰基，C.sub.1-5烷基氨基甲酰基或苯基氨基甲酰基; 或者当N(3)和C(4)原子之间存在双键时，R不存在; R.sup.1代表氢; 或者当N(3)和C(4)原子之间存在双键时，R.sup.1不存在; R.sup.2代表一个C.sub.1-3烷基; 或者R.sup.1和R.sup.2一起代表一个亚甲基基团，N(3)和C(4)原子之间没有双键存在; R.sup.3代表氢或一个C.sub.1-4烷酰基; R.sup.4代表氢; 一个C.sub.1-6烷酰基，可选地被一个甲氧基，氰基，羧基，氨基，C.sub.1-4烷基氨基，二(C.sub.1-4烷基)氨基，吡咯烷基，邻苯二甲酰亚胺基或苯基或一个或多个卤素取代; 以及一个苯甲酰基，棕榈酰基，环丙烷羰基，C.sub.1-5烷基氨基甲酰基或苯基氨基甲酰基; 虚线代表可能存在的价键，但要注意的是，当R.sup.3和R.sup.4都代表氢时，N(3)和C(4)原子之间不存在双键。一般式(I)的化合物具有有价值的中枢神经系统效应，特别是肌肉松弛、抗惊厥和神经保护作用。因此，它们可能对治疗中枢神经系统起源的各种疾病有用。
• N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic
  申请人：Cyogyszerkutato Intezet KFT

  公开号：US05639751A1

  公开（公告）日：1997-06-17

  The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) R stands for a C.sub.1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C.sub.1-4 alkylamino, di(C.sub.1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C.sub.1-5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R.sup.1 means hydrogen; or R.sup.1 is absent when a double bond exists between the N(3) and C(4) atoms; R.sup.2 means a C.sub.1-3 alkyl group; or R.sup.1 and R.sup.2 together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R.sup.3 means hydrogen or a C.sub.1-4 alkanoyl group; R.sup.4 represents hydrogen; a C.sub.1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C.sub.1-4 alkylamino, di(C.sub.1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropanecarbonyl, C.sub.1-5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R.sup.3 and R.sup.4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

  该发明涉及一种新颖的N-酰基-2,3-苯并二氮杂平衍生物，其一般式为(I)，它们的立体异构体和酸盐，含有它们的药物组合物以及它们的制备方法。在一般式(I)中，R代表一个C.sub.1-6烷酰基，该基可选择性地被甲氧基，氰基，羧基，氨基，C.sub.1-4烷基氨基，二(C.sub.1-4烷基)氨基，吡咯烷基，邻苯二甲酰亚胺或苯基取代，或者被一个或多个卤素取代；或者R是苯甲酰基，环丙烷羰基，C.sub.1-5烷基氨基甲酰基或苯基氨基甲酰基；或者当N(3)和C(4)原子之间存在双键时，R不存在；R.sup.1代表氢；或者当N(3)和C(4)原子之间存在双键时，R.sup.1不存在；R.sup.2代表一个C.sub.1-3烷基基团；或者R.sup.1和R.sup.2一起代表一个亚甲基基团，并且N(3)和C(4)原子之间不存在双键；R.sup.3代表氢或一个C.sub.1-4烷酰基；R.sup.4代表氢；一个C.sub.1-6烷酰基，该基可选择性地被甲氧基，氰基，羧基，氨基，C.sub.1-4烷基氨基，二(C.sub.1-4烷基)氨基，吡咯烷基，邻苯二甲酰亚胺或苯基取代，或者被一个或多个卤素取代；以及一个苯甲酰基，棕榈酰基，环丙烷羰基，C.sub.1-5烷基氨基甲酰基或苯基氨基甲酰基；虚线代表可能存在的化合价键，但要注意的是，当R.sup.3和R.sup.4都代表氢时，N(3)和C(4)原子之间不存在双键。一般式(I)的化合物具有有价值的中枢神经系统效应，特别是肌肉松弛、抗惊厥和神经保护作用。因此，它们可能对治疗中枢神经系统起源的各种疾病有用。
• Cycloaddition reactions with 2,3-benzodiazepine derivatives
  作者：Máriusz Kertész、István Pallagi、Sándor Sólyom

  DOI：10.1002/jhet.5570440224

  日期：2007.3

  We report here on some 3+2 dipolar cycloaddition reactions of propargyl, allyl and cyano substituted 2,3-benzodiazepines with in situ generated nitrile oxides and diazomethane. The reactivity of carbon-nitrogen double bonds of the 5H-[2,3]benzodiazepine ring system was also noticed.

  我们在这里报道了炔丙基，烯丙基和氰基取代的2,3-苯并二氮杂与原位生成的腈氧化物和重氮甲烷的一些3 + 2偶极环加成反应。还注意到5 H- [2，3]苯并二氮杂pine环系统的碳-氮双键的反应性。
• 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2177520A1

  公开（公告）日：2010-04-21

  The present invention provides compounds represented by the formula: or a salt thereof, wherein, each A1a and A3a are the same as or different from each other and each indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5 to 14-membered aromatic heterocyclic group; and W represents a halogen atom. The compounds are intermediates for the preparation of inhibitors of the AMPA receptor.

  本发明提供了以下式子或其盐的化合物，其中A1a和A3a分别相同或不同，每个表示一个选择性取代的C6-14芳香族烃环基或5至14元芳香族杂环基；W表示卤素原子。这些化合物是AMPA受体抑制剂的中间体。